Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HWH340 Tablets in BRCA1/2-mutated Metastatic Castration-resistant Prostate Cancer
CTR20223238Phase 2Completed
- Sponsor
- Hubei Institute of Biopharmaceutical Industry
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hwh340 in prostate cancer (PCa), sponsored by Hubei Institute of Biopharmaceutical Industry. Started Dec 2022; status: completed.
02
Drugs
hwh340
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20223238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223238.